Public health and valorization of genome-based technologies: a new model

Journal of Translational Medicine

Methodology

Tobias Schulte in den Bäumen¹  Jonathan A Lal¹  Angela Brand²  Servaas A Morré³ 

[1] Institute for Public Health Genomics, Department of Genetics & Cell Biology, CAPHRI, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 5, 6229 ES, Maastricht, The Netherlands;Institute for Public Health Genomics, Department of Genetics & Cell Biology, Research Institutes CAPHRI and GROW, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 5, 6229 ES, Maastricht, The Netherlands;Laboratory of Immunogenetics, Department of Pathology, VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands;Institute for Public Health Genomics, Department of Genetics & Cell Biology, Research Institutes CAPHRI and GROW, Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 5, 6229 ES, Maastricht, The Netherlands;

关键词: Technology Transfer;    Health Technology Assessment;    Public Health Genomics;    Health Needs Assessment;    Health Impact Assessment;    Valorization;    Translational Research;    Healthcare;    Health Policy;    Genomics;   

DOI  :  10.1186/1479-5876-9-207

 received in 2011-08-16, accepted in 2011-12-05,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundThe success rate of timely translation of genome-based technologies to commercially feasible products/services with applicability in health care systems is significantly low. We identified both industry and scientists neglect health policy aspects when commercializing their technology, more specifically, Public Health Assessment Tools (PHAT) and early on involvement of decision makers through which market authorization and reimbursements are dependent. While Technology Transfer (TT) aims to facilitate translation of ideas into products, Health Technology Assessment, one component of PHAT, for example, facilitates translation of products/processes into healthcare services and eventually comes up with recommendations for decision makers. We aim to propose a new model of valorization to optimize integration of genome-based technologies into the healthcare system.MethodsThe method used to develop our model is an adapted version of the Fish Trap Model and the Basic Design Cycle.ResultsWe found although different, similarities exist between TT and PHAT. Realizing the potential of being mutually beneficial justified our proposal of their relative parallel initiation. We observed that the Public Health Genomics Wheel should be included in this relative parallel activity to ensure all societal/policy aspects are dealt with preemptively by both stakeholders. On further analysis, we found out this whole process is dependent on the Value of Information. As a result, we present our LAL (Learning Adapting Leveling) model which proposes, based on market demand; TT and PHAT by consultation/bi-lateral communication should advocate for relevant technologies. This can be achieved by public-private partnerships (PPPs). These widely defined PPPs create the innovation network which is a developing, consultative/collaborative-networking platform between TT and PHAT. This network has iterations and requires learning, assimilating and using knowledge developed and is called absorption capacity. We hypothesize that the higher absorption capacity, higher success possibility. Our model however does not address the phasing out of technology although we believe the same model can be used to simultaneously phase out a technology.ConclusionsThis model proposes to facilitate optimization/decrease the timeframe of integration in healthcare. It also helps industry and researchers to come to a strategic decision at an early stage, about technology being developed thus, saving on resources, hence minimizing failures.

【 授权许可】

CC BY   
© Lal et al; licensee BioMed Central Ltd. 2011